Coya Therapeutics In Deal With Dr. Reddy's To License Proposed Biosimilar Abatacept For Coya 302

Coya Therapeutics, Inc. (COYA), a clinical-stage biotechnology company, announced Monday a worldwide agreement with Dr. Reddy's Laboratories Limited. (RDY).

Under the deal, Coya will in-license the proposed Abatacept biosimilar of Dr. Reddy's for the development of Coya's combination product for neurodegenerative diseases, COYA 302.

It is a dual biologic intended to suppress neuroinflammation via multiple immunomodulatory pathways, for the treatment of neurodegenerative conditions.

COYA 302 is comprised of two components - COYA 301 and CTLA4-Ig. Coya will develop COYA 301. Under the deal terms, Coya has been granted an exclusive, royalty-bearing license to Dr. Reddy's proposed biosimilar Abatacept for the development and commercialization of Coya 302 for the treatment of certain neurological diseases. The deal is for sale in multiple territories including North and South America, the EU, United Kingdom, and Japan.

As consideration for the license, Coya will pay a one-time non-refundable upfront fee to Dr. Reddy's. In addition, Coya will owe tiered payments to Dr. Reddy's based upon Coya's achievement of certain developmental milestones.

Coya will also owe royalties to Dr. Reddy's on net sales of Coya 302 within its licensed territory on a tiered basis. The companies said the agreement does not preclude Dr. Reddy's from launching its proposed biosimilar Abatacept globally for approved indications post regulatory approval.

Coya anticipates that it will file an IND for COYA 302 in the second hald of 2023 with the goal of initiating a phase 1b/2 trial in ALS (Amyotrophic Lateral Sclerosis) soon thereafter.

The deal also provides for the license of Coya 301, Coya's low dose IL-2 to Dr. Reddy's to permit the commercialization by Dr. Reddy's of Coya 302 in territories not otherwise granted to Coya. Coya will receive royalties on net sales by Dr. Reddy's in their territories based on the same tiered structure as Coya owes Dr. Reddy's.

The agreement also allows Dr. Reddy's and Coya to enter into a mutually satisfactory commercial supply agreement at an appropriate time.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
GameStop Corp. Wednesday disclosed that its Board of Directors has elected Chairman Ryan Cohen as Executive Chairman, effective immediately. In a filing with the U.S. Securities and Exchange Commission, the video game retailer said its Board on June 5 terminated Matthew Furlong as President and Chief Executive Officer with immediate effect. Shares of Inditex SA were gaining around 6 percent in the morning trading in Spain after the clothing firm that owns Zara reported Wednesday significant growth in its first-quarter profit on higher revenues as well as the absence of a prior year provision. Regarding the second quarter to date, the company said its store and online sales in constant currency between May 1 and June 4 increased 16.. The U.S. Consumer Product Safety Commission or CPSC, along with Golden, Colorado-based Boppy Co., urged consumers to stop using recalled Boppy Newborn Loungers, following reports of more infant deaths. They also asked online marketplaces to stop selling the recalled product. The company in September 2021 had recalled over 3.3 million infant lounging pillows after it was connected with deaths of 8
Follow RTT